Fracture incidence after 3 years of aromatase inhibitor therapy

Annals of Oncology

Volumn 25, Issue 4, 2014, Pages 843-847

  Bouvard, B ^a   Soulie P ^b   Hoppe E ^a   Georgin Mege, M ^b   Royer, M ^a   Mesgouez Nebout, N ^b   Lassalle, C ^a   Cellier, P ^b   Jadaud, E ^b   Abadie lacourtoisie, S ^b   Tuchais, C ^b   Vinchon petit, S ^b   Audran, M ^a   Chappard, D ^a   Legrand, E ^a  

^a UNIV Angers   (France)

^b Paul Papin Cancer Institute   (France)

Author keywords

Aromatase inhibitor; Bisphosphonate; Breast cancer; Osteoporosis; Vertebral fracture

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ADULT; ARTICLE; BONE DENSITY; BONE EXAMINATION; BREAST CANCER; CONTROLLED STUDY; FEMALE; FEMUR NECK; HUMAN; INCIDENCE; LONGITUDINAL STUDY; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SPINE FRACTURE; AGE; AGED; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; FRACTURE; MIDDLE AGED; PATHOLOGY;

AGE FACTORS; AGED; AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; POSTMENOPAUSE;

EID: 84897039266     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu008     Document Type: Article

References (20)

1. Aebi S, Davidson T, Gruber G et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 (Suppl 6): vi12-vi24.
2. Cuzick J, Sestak I, Baum M et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:10-year analysis of the ATAC trial. Lancet Oncol 2010;11:1135-1141.
3. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrineresponsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25: 486-492.
4. Rizzoli R, Body JJ, De Censi A et al. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int 2012;23:2567-2576.
5. Bouvard B, Hoppé E, Soulié P et al. High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy. Ann Oncol 2012; 23:1151-1156.
6. Van Poznak C, Hannon RA, Mackey JR et al. Prevention of aromatase inhibitorinduced bone loss using risedronate: the SABRE trial. J Clin Oncol 2012;28: 967-975.
7. Markopoulos C, Tzoracoleftherakis E, Polychronis A et al. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res 2010;12: R24.
8. Coleman R, de Boer R, Eidtmann H et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZOFAST study): final 60-month results. Ann Oncol 2013;24:398-405.
9. Ellis GK, Bone HG, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-4882.
10. Markopoulos C, Tzoracoleftherakis E, Koukouras D et al. Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. J Cancer Res Clin Oncol 2012;138: 1569-1577.
11. Riis BJ, Hansen MA, Jensen AM et al. Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone 1996;19:9-12.
12. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-787.
13. Eastell R, Adams J, Clack G et al. Long-term effects of anastrozole on bone mineral density:7-year results from the ATAC trial. Ann Oncol 2011;22: 857-862.
14. Nevitt MC, Cummings SR, Stone KL et al. Risk factors for a first-incident radiographic vertebral fracture in women > or =65 years of age: the study of osteoporotic fractures. J Bone Miner Res 2005;20:131-140.
15. Greenspan SL, Brufsky A, Lembersky BC et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008;26:2644-2652.
16. Reid DM, Hosking D, Kendler D et al. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis:24-month results from FACTS-International. Int J Clin Pract 2008; 62:575-584.
17. Boonen S, McClung MR, Eastell R et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004; 52:1832-1839.
18. Hochberg MC, Thompson DE, Black DM et al. Effect of alendronate on the agespecific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 2005; 20:971-976.
19. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822.
20. Brufsky AM, Harker WG, Beck JT et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012;118:1192-1201.